ArticleJournal of gastroenterology2026
Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a therapeutic challenge, characterized by poor prognosis and limited treatments. Despite the established role of cancer stemness in progression and resistance, current stemness-targeting strategies, including Notch pathway inhibition, have shown suboptimal clinical efficacy. This study investigates the mechanistic role of METTL3-mediated m6A modification in ESCC stemness regulation and explores the therapeutic potential of combining METTL3 inhibitors with Notch blockade.
methodsWe integrated multi-omics sequencing with functional validation. The METTL3/JAG2/Notch axis was systematically investigated using in vitro assays and in vivo xenograft models. Molecular mechanisms were elucidated through m6A-RNA immunoprecipitation, RNA stability assays, and exosome characterization.
resultsMETTL3 was significantly upregulated in ESCC and correlated with poor patient outcomes. Functionally, METTL3 enhanced ESCC cell proliferation, migration, and stemness maintenance through m6A-dependent regulation. Mechanistically, METTL3 catalyzed m6A modification on JAG2 mRNA, which was recognized and stabilized by IGF2BP2, leading to Notch pathway activation and upregulation of stemness markers (SOX9 and CD44). JAG2 mediated intercellular communication via both direct cell-cell contact and exosome-mediated signaling, promoting angiogenesis. Genetic ablation of JAG2 suppressed METTL3-driven tumor progression in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 exhibited synergy with Notch blockade, significantly enhancing anti-tumor efficacy in preclinical models.
conclusionsOur findings establish the METTL3/JAG2 axis as a critical regulator of ESCC progression through IGF2BP2-dependent m6A modification and Notch signaling activation. The demonstrated synergy between METTL3 inhibition and Notch pathway blockade provides a novel therapeutic strategy for ESCC treatment, addressing the unmet need for effective stemness-targeting therapies.
Indexed as
Identifiers
42274788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.